Welcome to our dedicated page for BioSig Technologies news (Ticker: BSGM), a resource for investors and traders seeking the latest updates and insights on BioSig Technologies stock.
BioSig Technologies, Inc. (Nasdaq: BSGM) is a Minneapolis-based medical technology company focused on the development and commercialization of advanced digital signal processing technology. The company aims to revolutionize the $3 billion electrophysiology (EP) market with its flagship product, the PURE EP™ Platform. This FDA-cleared, non-invasive class II device combines innovative hardware and software to provide unparalleled clarity and precision in visualizing intracardiac signals. The technology facilitates highly targeted cardiac ablation procedures, improving procedural efficiency and patient outcomes.
BioSig's commitment to addressing healthcare's critical priorities—saving time, reducing costs, and saving lives—is reflected in its collaborative efforts with leading medical centers, including the Cleveland Clinic, Mayo Clinic, and Texas Cardiac Arrhythmia Institute. The PURE EP™ Platform's Near-Field Tracking (NFT) algorithm, introduced in Q4 2023, has already demonstrated a significant reduction in ablation time by approximately 66%, highlighting its potential to enhance clinical procedures.
Despite recent challenges, including workforce reductions and strategic shifts, BioSig remains focused on expanding its product's adoption and exploring new market opportunities. The company recently appointed Bridge Associates International Pharmaceutical Consulting (BAIPC) to advise on business model strategies and continues to work on potential commercialization opportunities within the AI space.
Under the leadership of a new CEO and a reconstituted Board of Directors, BioSig is committed to restoring and creating lasting shareholder value. The company has also addressed compliance issues with the Nasdaq Hearings Panel, further solidifying its position in the marketplace.
For more information and the latest updates, visit the SEC's website.
BioSig Technologies (Nasdaq: BSGM) announced a Phase 2 clinical trial of merimepodib in conjunction with remdesivir for hospitalized COVID-19 patients requiring advanced respiratory support. The randomized, double-blind study is being conducted at five sites across the U.S., directed by Dr. Andrew Badley from Mayo Clinic. The trial evaluates the safety and efficacy of merimepodib, which has shown in vitro antiviral activity against SARS-CoV-2. A conference call is scheduled for September 22, 2020, to discuss trial insights and future plans.
BioSig Technologies, Inc. (Nasdaq: BSGM) will host a conference call on September 15, 2020, at 11:00 AM ET to discuss the initial results from the PURE EP 2.0 Clinical Study, focusing on atrial fibrillation ablation procedures. The blinded, randomized data was presented at ESC Congress 2020 and collected at St. David’s Medical Center in Austin, Texas. The PURE EP System aims to enhance ECG and intra-cardiac signal fidelity. A replay will be available starting September 15. For further details, visit www.biosig.com.
BioSig Technologies (NASDAQ: BSGM) will present at the 12th Annual LD 500 Conference on September 2, 2020, at 11:40 AM ET. The presentation, led by Kenneth L. Londoner, will highlight the company’s advancements, including the installation of its PURE EP™ System at Massachusetts General Hospital. Additionally, BioSig's subsidiary, ViralClear Pharmaceuticals, is conducting a Phase 2 clinical study for the COVID-19 treatment merimepodib in combination with remdesivir. Attendees can register for the event through the provided links.
BioSig Technologies, Inc. (NASDAQ: BSGM) is set to present at the 12th Annual LD 500 Conference on September 2, 2020, at 11:40 AM ET. Kenneth L. Londoner, the Company's Chairman and CEO, will discuss recent developments, including the installation of the PURE EP™ System at Massachusetts General Hospital as part of a clinical study. Additionally, BioSig’s subsidiary, ViralClear Pharmaceuticals, is enrolling patients for a Phase 2 clinical study of merimepodib in combination with remdesivir for COVID-19 treatment.
BioSig Technologies' subsidiary, ViralClear Pharmaceuticals, has appointed Professor Angus Dalgleish to its Scientific Advisory Board, enhancing its expertise in antiviral drug development. ViralClear is currently conducting Phase 2 trials of merimepodib, a treatment for COVID-19, which has shown strong antiviral activity against SARS-CoV-2 in cell cultures. The Scientific Advisory Board aims to oversee drug discovery and address emerging viral infections. This strategic addition reflects the company's commitment to combating COVID-19 and strengthens its leadership team.
BioSig Technologies (Nasdaq: BSGM) announced the appointment of Dr. Michael J. Sofia to its subsidiary ViralClear Pharmaceuticals' Scientific Advisory Board. Dr. Sofia, an esteemed researcher with over 110 publications and a pivotal inventor of sofosbuvir, aims to leverage his extensive experience in antiviral drug development to advance ViralClear's COVID-19 treatment, merimepodib. Currently in Phase 2 trials, merimepodib shows promise against SARS-CoV-2 and previously completed 12 clinical trials with a strong safety profile.
BioSig Technologies (BSGM) announced the installation of its PURE EP™ System at Massachusetts General Hospital as part of an expanded clinical study. Under the leadership of Dr. Moussa Mansour, the evaluation will advance the Company's efforts in cardiac signal processing. This follows ongoing studies at Texas Cardiac Arrhythmia Research Foundation and Mayo Clinic. The Company aims to tap into the recovering atrial fibrillation market, emphasizing the significance of patient cases for healthcare outcomes.
BioSig Technologies, Inc. (BSGM), a medical technology firm, has secured a Commercial and Government Entity (CAGE) code from the Systems for Award Management (SAM). This code enables BioSig and its subsidiary, ViralClear, to engage in business with U.S. government agencies and pursue government contracts effectively.
The CAGE code positions BioSig to apply for government contracts and assistance programs, potentially opening new revenue streams for the company.
BioSig Technologies (Nasdaq: BSGM) announced updates on its PURE EP(tm) System installations and the Phase 2 clinical study of merimepodib combined with remdesivir for COVID-19 patients. Kenneth L. Londoner, the Chairman and CEO, will present at the Proactive Investors One2One Virtual Event on August 4, 2020, at 1 PM ET. The company's technology aims to enhance ECG and intra-cardiac signal fidelity, while its subsidiary, ViralClear Pharmaceuticals, is developing merimepodib, an antiviral candidate previously explored for other conditions.
BioSig Technologies, Inc. (Nasdaq: BSGM), a medical tech company, announced its presentation at LD Micro’s Zooming with LD event on July 27, 2020. Kenneth L. Londoner, Chairman and CEO, will discuss company updates including the PURE EP(tm) system installations and the Phase II clinical study of its COVID-19 treatment, merimepodib. With a 34% stock increase this year, BioSig emphasizes its strong position for value creation. Investors can register for the 8 am PST presentation and one-on-one meetings on the same day.
FAQ
What is the current stock price of BioSig Technologies (BSGM)?
What is the market cap of BioSig Technologies (BSGM)?
What does BioSig Technologies, Inc. do?
What is the PURE EP™ Platform?
Who are BioSig's collaborators?
What recent achievements has BioSig made?
How is BioSig addressing its financial and operational challenges?
What are BioSig's future plans?
How does the NFT algorithm benefit clinical procedures?
Is BioSig publicly traded?
What steps has BioSig taken to comply with Nasdaq requirements?
Where can I find more information about BioSig?
